The utility of prostate-specific antigen as a surrogate marker for identification of high-risk cohorts and assessing response in chemoprevention trials.
Serum prostate-specific antigen (PSA) is the most important tumor marker in oncology practice. It may assume a similar role in chemoprevention strategies. It is a simple and reproducible blood test that can both identify a high-risk cohort and provide meaningful information regarding the response to intervention. A wealth of information is available regarding the relationship of PSA to age, race and velocity. Free and total values may serve to further define high-risk cohorts and provide a barometer for response and disease presence in chemoprevention trials.
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis*; D002986:Clinical Trials as Topic; D015331:Cohort Studies; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D017430:Prostate-Specific Antigen / Q000032:analysis / Q000097:blood*; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000517:prevention & control*; D012680:Sensitivity and Specificity